Ginkgo Bioworks Holdings, Inc.
DNA · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Market Cap | $811 | $617 | $309 | $510 |
| - Cash | $111 | $204 | $312 | $562 |
| + Debt | $423 | $429 | $435 | $468 |
| Enterprise Value | $1,123 | $842 | $431 | $416 |
| Revenue | $39 | $50 | $48 | $44 |
| % Growth | -21.7% | 2.7% | 10.2% | – |
| Gross Profit | $26 | $35 | $36 | $34 |
| % Margin | 67% | 70.1% | 75.1% | 78.1% |
| EBITDA | -$67 | -$46 | -$68 | -$143 |
| % Margin | -171.4% | -92.9% | -141.4% | -327.2% |
| Net Income | -$81 | -$60 | -$91 | -$108 |
| % Margin | -207.9% | -121.6% | -188.2% | -245.2% |
| EPS Diluted | -1.45 | -1.1 | -1.68 | -2.07 |
| % Growth | -31.8% | 34.5% | 18.8% | – |
| Operating Cash Flow | -$32 | -$40 | -$52 | -$42 |
| Capital Expenditures | $0 | -$0 | -$8 | -$14 |
| Free Cash Flow | -$32 | -$40 | -$59 | -$56 |